Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Dabigatran

Dabigatran

Dabigatran is a direct thrombin inhibitor used to prevent stroke and blood clots in patients with atrial fibrillation.
It works by blocking the activity of thrombin, a key enzyme in the blood clotting process.
Dabigatran has been shown to be effective in reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and is approved for use in this indication.
Researchers can use PubCompare.ai's AI-driven platform to optimize Dabigatran research protocols, locate the best protocols from literature, pre-prints, and patents, and enhance reproducibility and accuaracy through intelligent comparissons.

Most cited protocols related to «Dabigatran»

1
Replicating a Published Observational Study
To demonstrate the utility of standardizing disparate data sources into a CDM, we replicated a published observational study protocol and evaluated the quality of a standardized approach and time-to-execution. As an exemplar, we used the Mini-Sentinel analysis of the comparative effectiveness of rivaroxaban versus warfarin on various outcomes in patients with atrial fibrillation.30 We developed a standardized analytic routine that replicated the cohort definitions within the protocol and applied the analytic program across all 6 databases to compare the impact of the inclusion criteria on the proportion of patients qualifying for the study.
Specifically, we identified all new users of each target drug (warfarin and rivaroxaban) who satisfied the following 7 criteria of the original study: (1) had at least 183 days of nonexposure before the first target drug exposure; (2) had at least 1 atrial fibrillation or atrial flutter diagnosis code within the 183-day window prior to first exposure; (3) did not have any prior diagnosis or procedure codes indicative of long-term dialysis; (4) did not have any prior diagnosis or procedure codes indicative of kidney transplant; (5) did not have any prior diagnosis or procedure code indicative of mitral stenosis or mechanical heart valve; (6) did not have any prior procedure code indicative of joint replacement or arthroplasty surgery; and (7) did not have prior use of any anticoagulant (warfarin, rivaroxaban, dabigatran, or apixaban). For each target drug, we created 2 cohorts: new users of the drug (defined by satisfying criteria No. 1), and the subset of those new users of the drug who satisfied the remaining 6 criteria. For each cohort, we produced a standardized descriptive summary of the population, including demographics (gender and age distribution), comorbidities (prevalence of conditions in time window prior to cohort entry), concomitant medications (prevalence of drug exposure in time window prior to cohort entry), and service utilization (prevalence of procedures in time window prior to cohort entry). We measured the execution time for the standardized analytic routine when applied to each target drug across all 6 databases. Analyses were conducted on a Microsoft Server 2008 (Microsoft Corporation, Redmond, Washington) with an AMD Opteron 6172 (Advanced Micro Devices, Inc, Sunnyvale, California), 2.10 GHz, 2 processors, 24-core CPU, and 256 GB of RAM. Each CDM was stored in a separate database within an instance of Microsoft SQL Server 2012 (Microsoft Corporation, Redmond, Washington).
Appendix 1 contains the standard concepts and corresponding source codes that were used to define each of the core concepts required within the prespecified protocol.
Voss E.A., Makadia R., Matcho A., Ma Q., Knoll C., Schuemie M., DeFalco F.J., Londhe A., Zhu V, & Ryan P.B. (2015). Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association : JAMIA, 22(3), 553-564.
Publication 2015
Anticoagulants apixaban Arthroplasty Arthroplasty, Replacement Atrial Fibrillation Atrial Flutter Dabigatran Diagnosis Dialysis Drug Abuser Drug Delivery Systems Heart, Artificial Heart Valves Kidney Transplantation Medical Devices Mitral Valve Stenosis Operative Surgical Procedures Patients Pharmaceutical Preparations Rivaroxaban Warfarin
2
Andexanet Alfa for Acute Major Bleeding
Patients were enrolled at 63 centers in North America and Europe. Patients were eligible if they were at least 18 years of age, presented with acute major bleeding, and had received within 18 hours one of the following: apixaban, rivaroxaban, or edoxaban at any dose or enoxaparin at a dose of at least 1 mg per kilogram of body weight per day. Acute major bleeding was defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise (e.g., severe hypotension, poor skin perfusion, mental confusion, or low cardiac output that could not otherwise be explained); bleeding associated with a decrease in the hemoglobin level of at least 2 g per deciliter (or a hemoglobin level of ≤8 g per deciliter if no baseline hemoglobin level was available); or bleeding in a critical area or organ (e.g., retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome). Written informed consent was obtained from all the patients, whether directly from the patient, by proxy consent from a legally authorized representative, or by emergency consent (as described in the Supplementary Appendix, available at NEJM.org).
Patients were enrolled from April 2015 through May 2018. From July 2016 through August 2017, only patients with intracranial hemorrhage were enrolled to enrich the study with these patients. After August 2017, patients with all types of bleeding except visible, musculoskeletal, or intraarticular bleeding were enrolled. Substantive amendments to the enrollment criteria during the trial are presented in the Supplementary Appendix.
Key exclusion criteria were planned surgery within 12 hours after andexanet treatment (with the exception of minimally invasive operations or procedures); intracranial hemorrhage in a patient with a score of less than 7 on the Glasgow Coma Scale (scores range from 15 [normal] to 3 [deep coma]) or an estimated hematoma volume of more than 60 cc; expected survival of less than 1 month; the occurrence of a thrombotic event within 2 weeks before enrollment; or use of any of the following agents within the previous 7 days: vitamin K antagonist, dabigatran, prothrombin complex concentrate, recombinant factor VIIa, whole blood, or plasma.
Connolly S.J., Crowther M., Eikelboom J.W., Gibson C.M., Curnutte J.T., Lawrence J.H., Yue P., Bronson M.D., Lu G., Conley P.B., Verhamme P., Schmidt J., Middeldorp S., Cohen A.T., Beyer-Westendorf J., Albaladejo P., Lopez-Sendon J., Demchuk A.M., Pallin D.J., Concha M., Goodman S., Leeds J., Souza S., Siegal D.M., Zotova E., Meeks B., Ahmad S., Nakamya J, & Milling TJ J.r. (2019). Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. The New England journal of medicine, 380(14), 1326-1335.
Publication 2019
andexanet apixaban BLOOD Body Weight Comatose Compartment Syndromes Dabigatran edoxaban Emergencies Enoxaparin Factor IX Complex Hematoma Hemodynamics Hemoglobin Hemoglobin A Intracranial Hemorrhage Minimally Invasive Surgical Procedures Operative Surgical Procedures Patients Perfusion Pericardium Plasma recombinant FVIIa Retroperitoneal Space Rivaroxaban Skin Vitamin K
3
Dabigatran Adherence and Outcomes

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Dabigatran Ethics Committees, Research Hypersensitivity Patients Therapeutics Warfarin
4
GLORIA-AF Registry Multinational AF Study
GLORIA-AF was an international, multi-center, non-interventional registry program, based on prospectively collected data for patients with newly diagnosed AF. Participating centers were selected to achieve a country-specific balance of health care settings. The three-phased design of the GLORIA-AF Registry Program has previously been published (Fig. 1) [12 (link)]. To reduce confounding, Phase III of the program only started once relevant baseline characteristics of patients initiating dabigatran and VKA in Phase II were sufficiently similar to allow for comprehensive comparative analysis, as determined by propensity score (PS) methodology. All patients in GLORIA-AF were managed according to local clinical practice and treatment decisions were solely at the discretion of the treating physician. Patients included in Phase III were followed for 3 years, regardless of prescribed antithrombotic therapy.

Design of GLORIA-AF. m, months; NOAC non-vitamin K antagonist oral anticoagulant; VKA vitamin K antagonist; y, years

GLORIA-AF was conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki and Good Epidemiological Practice and Good Pharmacoepidemiology Practices, and the protocol was approved by the European Medicines Agency and institutional review boards at each participating site. Patients provided written informed consent. An independent, academic steering committee oversaw the design, execution, and study conduct, and was responsible for manuscript development. Extensive measures were undertaken to ensure accurate and complete reporting of outcomes and minimize loss to follow-up. Clinical data and site characteristics were captured using a web-based system over a secure network to ensure confidentiality and data integrity. The Data Sharing Statement is included in the Supplementary Information.
Huisman M.V., Teutsch C., Lu S., Diener H.C., Dubner S.J., Halperin J.L., Ma C.S., Rothman K.J., Lohmann R., Gurusamy V.K., Bartels D.B, & Lip G.Y. (2022). Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. Clinical Research in Cardiology, 111(5), 548-559.
Publication 2022
Anticoagulants Dabigatran Ethics Committees, Research Europeans N(4)-oleylcytosine arabinoside Patients Pharmaceutical Preparations Physicians Therapeutics Vitamin K
5
Propensity Score Matching of Novel Oral Anticoagulants
One-to-one propensity score matching (PSM) was conducted between NOACs and warfarin (apixaban versus warfarin, dabigatran versus warfarin, and rivaroxaban versus warfarin) and between the NOACs (apixaban versus dabigatran, apixaban versus rivaroxaban, and dabigatran versus rivaroxaban). Patients were matched 1:1 in each data set based on the propensity scores generated by logistic regression based on demographics, Charlson Comorbidity Index score,14 (link) baseline bleeding and stroke/SE history, comorbidities, and baseline comedications (complete list of covariates in Table II in the online-only Data Supplement). Nearest neighbor matching method without replacement with a caliper of 0.01 was used to match the patients.15 (link) The balance of covariates was checked based on standardized differences with a threshold of 10%.16 (link) Study patients from the 5 datasets were pooled for analysis after ensuring cohorts were balanced.
After PSM, the rate of stroke/SE and MB in each PSM cohort was evaluated with Cox proportional hazard models with robust sandwich estimates.15 (link) OAC treatment was included as the independent variable, and no other covariates were included in the model because the cohorts were balanced.
Lip G.Y., Keshishian A., Li X., Hamilton M., Masseria C., Gupta K., Luo X., Mardekian J., Friend K., Nadkarni A., Pan X., Baser O, & Deitelzweig S. (2018). Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients: The ARISTOPHANES Study. Stroke, 49(12), 2933-2944.
Publication 2018
apixaban Cerebrovascular Accident Dabigatran Dietary Supplements N(4)-oleylcytosine arabinoside Patients Rivaroxaban Warfarin

Most recents protocols related to «Dabigatran»

1
Anticoagulation Therapy Post-PCI: Balancing Stroke and VTE
Patients were identified from queries of electronic medical records using International Classification of Disease 9th or 10th edition (ICD-9/10) and Current Procedural Terminology (CPT) codes for AF, VTE, and PCI. Electronic discharge records of hospitalized patients with ICD-10 codes in “any” diagnostic position for AF and/or VTE and CPT codes for PCI were manually reviewed to verify proper categorization of those receiving anticoagulation therapy to prevent stroke for AF or treatment of VTE who underwent PCI with placement of one or more drug-eluting stents. Adult patients (age 18 + years) who were 12 months (± 1 month) status post PCI and who were concurrently receiving oral anticoagulant (OAC) therapy with warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban were considered for study inclusion. Patients initiating OAC therapy either before or after PCI were included providing that 12-months (± 1 month) had elapsed since the index PCI. Patients with mechanical heart valve prostheses and placement of bare metal stents during index PCI were excluded as were those with insufficient information in their medical record to allow categorization of antithrombotic pathways or clinical outcomes. An overview of the study design is provided in the Fig. 1. Baseline characteristics collected administratively or during manual medical record reviews included age, sex, race, ethnicity, comorbid diseases, reason for PCI (ACS/MI or SIHD), oral anticoagulant type, Charlson Comorbidity Index (CCI) and CHA2DS2-VASc scores (patients with AF).

Overview of study patient identification, flow, and outcomes. MACNE- major adverse cardiovascular or neurological events

Gamvroulas E.M., Jones A.E., Saunders J.A., Jones T.L, & Witt D.M. (2023). Trends in antiplatelet strategies 12-months following coronary stent placement in anticoagulated patients. BMC Cardiovascular Disorders, 23, 117.
Publication 2023
Adult Anticoagulants apixaban Cardiovascular System Cerebrovascular Accident Dabigatran Diagnosis Drug-Eluting Stents edoxaban Ethnicity Heart Valve Prosthesis Metals Patient Discharge Patients Rivaroxaban Stents Therapeutics Warfarin
2
Restricted Medication Management in Study

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Anti-Inflammatory Agents, Non-Steroidal Anticoagulants Antirheumatic Drugs, Disease-Modifying apixaban Arthritis Aspirin Atorvastatin Biopharmaceuticals Central Nervous System Agents Dabigatran Diazepam Duloxetine Eliquis Ezetimibe Ezetrol Gabapentin Heparin Hydroxymethylglutaryl-CoA Reductase Inhibitors lipid I Muscle Tissue Opioids Pain Pharmaceutical Preparations Pradaxa Pravastatin Pregabalin Rivaroxaban Simvastatin Steroids tetrazepam Tramadol Warfarin Xarelto
3
Venous Thromboembolism Risk in Elderly Arthroplasty
Inclusion criteria: A total of 1540 patients aged 60 years or older who were
diagnosed with OA or RA before undergoing TJA in our hospital between January
2017 and December 2021.
Exclusion criteria: (1) a history of VTE (3 cases); (2) use of anticoagulation
medications (aspirin, clopidogrel, warfarin, rivaroxaban, dabigatran): atrial
fibrillation (4 cases), coronary heart disease (CHD) patients with installed
stents and anticoagulant therapy (5 cases); (3) joint infection: knee joint (6
cases); (4) tuberculosis of the joint (10 cases); (5) tumors of the joints (10
cases); (6) thrombophilia genetic disorders (0 cases); (7) no preoperative lower
extremity ultrasound records (111 cases); (8) no routine blood test records (0
cases). Finally, a total of 1391 patients were enrolled.
Xiong X., Li T., Yu S, & Cheng B. (2023). Association Between Platelet Indices and Preoperative Deep Vein Thrombosis in Elderly Patients Undergoing Total Joint Arthroplasty: A Retrospective Study. Clinical and Applied Thrombosis/Hemostasis, 29, 10760296221149699.
Publication 2023
Anticoagulants Aspirin Clopidogrel Dabigatran Heart Disease, Coronary Hematologic Tests Hereditary Diseases Infection Joints Joint Tuberculosis Knee Joint Neoplasms Patients Rivaroxaban Therapeutics Thrombophilia Ultrasonics Warfarin
4
Bone Marrow Biopsy with MEOPA Sedation
Eligible patients were aged 18 years and older with previously documented or suspected untreated malignant hemopathy with an indication for a bone marrow biopsy. An Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2 and normal biological coagulation parameters were required. Clinical examination and bone pelvic imaging were performed before inclusion to exclude iliac lymphoma localization. The exclusion criteria were pregnancy, congenital or acquired coagulation deficit, thrombocytopenia less than 50,000/mm3, and use of certain drugs (fluindione, acenocoumarol, warfarin, dabigatran, apixaban, rivaroxaban, and analgesics for chronic pain). We also excluded patients for whom MEOPA was not recommended (intracranial hypertension, allergy, severe lung failure with oxygen therapy, emphysema, pneumothorax, recent history of air embolism, epilepsy, and vitamin B12 and B9 deficiencies) and those in whom 3-dimensional movies (pacemaker or defibrillator) were contraindicated.
Le Du K., Septans A.L., Maloisel F., Vanquaethem H., Schmitt A., Le Goff M., Clavert A., Zinger M., Bourgeois H., Dupuis O., Denis F, & Bouchard S. (2023). A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study. Journal of Medical Internet Research, 25, e38619.
Publication 2023
Acenocoumarol Air Embolism Analgesics apixaban Biopharmaceuticals Biopsy Bone Marrow Bones Chronic Pain Coagulation, Blood Cobalamins Dabigatran Defibrillators Epilepsy fluindione Hypersensitivity Ilium Lung Lymphoma Meopa Neoplasms Pacemaker, Artificial Cardiac Patients Pelvis Pharmaceutical Preparations Physical Examination Pneumothorax Pregnancy Pulmonary Emphysema Rivaroxaban Therapies, Oxygen Inhalation Thrombocytopenia Warfarin
5
Anticoagulant Prescription Patterns in Cirrhosis
Information regarding patient characteristics, including demographics, clinical comorbidities, and medication use was ascertained for each patient during the baseline assessment period. Clinical characteristics included age, sex, calendar year, severity of cirrhosis (defined by prior decompensation events, including ascites, spontaneous bacterial peritonitis, bleeding esophageal varices, hepatic encephalopathy, and hepatorenal syndrome), coagulopathy, thrombocytopenia, prior bleeding events, chronic kidney disease or end‐stage renal disease (CKD/ESRD), CHA2DS2VASc score (calculated as 1 point each for congestive heart failure, hypertension, age ≥75 [point doubled], diabetes, prior stroke or transient ischemic attack or thromboembolism [point doubled], vascular disease, age 65–74, female sex), and HAS‐BLED score (calculated as 1 point each for hypertension, abnormal renal function, abnormal liver function or cirrhosis [all patients received this point], prior stroke, prior major bleeding or predisposition to bleeding, a labile international normalized ratio, age >65 years, prior alcohol or drug use history, or use of medications that predispose to bleeding).14, 26 All comorbidities were identified by ICD‐9 and ICD‐10 codes (see Table S1 for details).
Within the study cohort, the primary outcome was prescription of an OAC (including warfarin and the individual DOACs, apixaban, rivaroxaban, or dabigatran) in the 6 months following (and including) the cohort entry date, between 2012 and 2019.
Simon T.G., Schneeweiss S., Singer D.E., Sreedhara S.K, & Lin K.J. (2023). Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 12(3), e026863.
Publication 2023
apixaban Ascites Bacteria Blood Coagulation Disorders Cerebrovascular Accident Chronic Kidney Diseases Congestive Heart Failure Dabigatran Diabetes Mellitus Esophageal Varices Ethanol Females Hepatic Encephalopathy Hepatorenal Syndrome High Blood Pressures International Normalized Ratio Kidney Kidney Failure, Chronic Liver Cirrhosis Patients Peritonitis Pharmaceutical Preparations Rivaroxaban Thrombocytopenia Thromboembolism Transient Ischemic Attack Vascular Diseases Warfarin

Top products related to «Dabigatran»

1
Dabigatran by Boehringer Ingelheim
Sourced in Germany
Dabigatran is a direct thrombin inhibitor, a type of anticoagulant medication used to prevent and treat blood clots. It works by blocking the activity of thrombin, a key enzyme involved in the blood clotting process. Dabigatran is presented in the form of a pharmaceutical product for clinical use.
2
Dabigatran by Merck Group
Sourced in United States
Dabigatran is a direct thrombin inhibitor, a type of anticoagulant medication used to prevent and treat blood clots. It functions by interfering with the activity of thrombin, a key enzyme in the blood clotting process.
3
Thrombin by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Switzerland, Sweden, Ireland, Macao, India, Australia, France, Spain
Thrombin is a serine protease enzyme that plays a crucial role in the blood coagulation process. It is responsible for the conversion of fibrinogen to fibrin, which is the main structural component of blood clots. Thrombin also activates other factors involved in the clotting cascade, promoting the formation and stabilization of blood clots.
4
Sta liquid anti xa by Diagnostica Stago
Sourced in France
The STA®-Liquid Anti-Xa is a laboratory equipment product manufactured by Diagnostica Stago. It is used for the quantitative determination of heparin (unfractionated and low molecular weight) and fondaparinux in plasma samples.
5
Acltop coagulation analyzer by Werfen
Sourced in United States
The ACLTOP coagulation analyzer is a laboratory instrument designed to perform automated analysis of coagulation tests. It is capable of measuring various coagulation parameters, such as prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen. The ACLTOP provides accurate and reliable results to support clinical decision-making in the field of hemostasis and thrombosis.
6
Dabigatran etexilate by Boehringer Ingelheim
Sourced in Germany
Dabigatran etexilate is a direct thrombin inhibitor. It is a pharmaceutical product used in the treatment and prevention of various thromboembolic disorders.
7
Sta eca 2 by Diagnostica Stago
Sourced in France
The STA-ECA II is a laboratory equipment product manufactured by Diagnostica Stago. It is designed to perform coagulation and hemostasis testing. The core function of the STA-ECA II is to analyze blood samples and provide objective data on the patient's coagulation profile.
8
Dabigatran by Alsachim
Sourced in France
Dabigatran is a pharmaceutical product designed for analytical laboratories. It functions as a direct thrombin inhibitor, which is a type of anticoagulant drug used in the treatment and prevention of blood clots. This product is intended for research and analytical use only, and its specific applications should be determined by the end-user.
9
Dabigatran by LGC
Sourced in Canada, United States
Dabigatran is a laboratory reagent used for the quantitative determination of direct thrombin inhibitor (DTI) concentrations in plasma samples. It is a synthetic, reversible, direct thrombin inhibitor that binds directly to thrombin, preventing the conversion of fibrinogen to fibrin. Dabigatran is commonly used in coagulation and hemostasis research and testing applications.
10
Rivaroxaban by LGC
Sourced in Canada, United States
Rivaroxaban is a laboratory-grade product designed for research and analytical purposes. It is a direct factor Xa inhibitor used to measure and analyze blood coagulation and related parameters in various research and diagnostic applications.

More about "Dabigatran"

Dabigatran is a direct-acting oral anticoagulant (DOAC) that functions as a potent and selective inhibitor of thrombin, a critical enzyme in the blood coagulation cascade.
This medication is primarily utilized to prevent stroke and systemic embolism in patients diagnosed with non-valvular atrial fibrillation, a common heart rhythm disorder.
Thrombin plays a pivotal role in the formation of blood clots, as it catalyzes the conversion of fibrinogen to fibrin, the key structural component of a thrombus.
By directly inhibiting thrombin's enzymatic activity, dabigatran effectively disrupts this clotting process, reducing the risk of potentially life-threatening thromboembolic events.
Researchers can leverage PubCompare.ai's innovative AI-driven platform to optimize their dabigatran-related research protocols.
This platform empowers researchers to locate the most effective protocols from the existing literature, preprints, and patent data through intelligent comparisons.
This approach enhances the reproducibility and accuracy of dabigatran research, leading to more robust and reliable findings.
In addition to dabigatran, other anticoagulant agents such as rivaroxaban and STA®-Liquid Anti-Xa, as well as coagulation analysis tools like the ACLTOP coagulation analyzer and STA-ECA II, may be used in thrombosis research and management.
By understanding the broader landscape of anticoagulation therapies and diagnostic technologies, researchers can make more informed decisions and develop more comprehensive research strategies.
By incorporating these insights and leveraging the power of AI-driven research platforms like PubCompare.ai, researchers can optimize their dabigatran-related studies, leading to advancements in the prevention and management of thromboembolic disorders.